Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $15.00 target price on the stock.
Several other equities analysts have also recently issued reports on IMRX. Chardan Capital restated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $12.80.
Get Our Latest Research Report on IMRX
Immuneering Trading Down 3.0 %
Institutional Investors Weigh In On Immuneering
Several large investors have recently modified their holdings of IMRX. Marshall Wace LLP acquired a new position in Immuneering in the second quarter valued at $492,000. Renaissance Technologies LLC acquired a new position in shares of Immuneering in the 2nd quarter valued at about $447,000. Acadian Asset Management LLC bought a new stake in shares of Immuneering during the 2nd quarter valued at about $67,000. Tidemark LLC acquired a new stake in Immuneering during the third quarter worth approximately $129,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering during the second quarter worth approximately $44,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Further Reading
- Five stocks we like better than Immuneering
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- 10 Best Airline Stocks to Buy
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.